Glion AI Biotherapeutics
Stealth Mode
Company Overview
Snapshot
Founded in May 2023 by Ilan Sinai and Aviv De Morgan, Glion AI Biotherapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technologies.
Business overview
Glion AI Biotherapeutics is a Health Tech & Life Sciences company operating in stealth mode, specializing in Pharma & Medical Biotechnology. The company leverages artificial intelligence, including deep learning, machine learning, and natural language processing, alongside advanced biological technologies such as molecules, genes, and cells. It also utilizes cloud-based data storage and synthetic data for simulation and imaging. Glion AI Biotherapeutics develops software platforms and interfaces, targeting the healthcare and life sciences industries with a focus on areas like oncology, orphan drugs, rare diseases, amyotrophic lateral sclerosis (ALS), degenerative diseases, and autoimmune diseases. Its product development is currently in the R&D stage, with a business model centered on B2B interactions.
Company Intelligence Q&A
- When was Glion AI Biotherapeutics founded?
- Glion AI Biotherapeutics was founded in May 2023.
- Who are the founders of Glion AI Biotherapeutics?
- The founders of Glion AI Biotherapeutics are Ilan Sinai and Aviv De Morgan.
- What is the primary sector of Glion AI Biotherapeutics?
- Glion AI Biotherapeutics operates primarily in the Health Tech & Life Sciences sector.
- What is the current employee count for Glion AI Biotherapeutics?
- Glion AI Biotherapeutics currently has 1–10 employees.